Press release


22/04/2014
SOM Biotech develops a drug for Amyloidosis in collaboration with the Vall d’Hebron Research Institute
SOM Biotech_VHIR
The VHIR and the biopharmaceutical SOM Biotech have signed an agreement to jointly develop the clinical phase of a drug for transthyretin Amyloidosis (ATTR). The collaboration starts with the execution of a proof of concept which will confirm the efficacy and safety of compound SOM0226. The product, a repositioned drug developed by SOM Biotech, has been designated recently orphan drug by the FDA.
 
 
 
 
 
Permalink  
 
Developed by Web4Bio